Half of people with worse liver function responded well to immunotherapy.

Whether such recurrence is less likely after interferon treatment remains the source of some controversy in the hep C research community.

Liver fat may be a driver of increased cancer risk associated with obesity.

A second immunotherapy option is now available for hepatocellular carcinoma.

Investigators have found biomarkers that might one day be used to help detect liver cancer during earlier stages.

Scientists aren’t sure, but they know that the risk that a previous case of liver cancer will return remains high for those cured of hep C.

Other pain relievers might raise the odds, however.

Although the risk is low, periodic medical monitoring for liver cancer among those with hepatitis B surface antigen clearance is advised.

Researchers analyzed a cohort of South Koreans taking Viread (tenofovir disoproxil fumarate) or Baraclude (entecavir) for hepatitis B.